Interpreting Adjuvant Intensification Data and Selecting the Right Patient in Advanced RCC

This section focuses on emerging adjuvant trial data, including studies evaluating intensification strategies beyond single agent pembrolizumab. The panel discusses how disease free survival improvements must be interpreted in the context of absolute risk reduction and patient specific factors.

A key theme is that not all high risk patients derive equal benefit from escalation. Younger individuals with aggressive pathological features may accept increased toxicity in exchange for recurrence reduction. In contrast, older patients with competing comorbidities may prioritize minimizing treatment related adverse effects.

The downstream implications of adjuvant therapy are also addressed. Decisions made in the adjuvant setting can influence future metastatic options. Clinicians must weigh early toxicity risk and potential long term immune related effects against possible benefit in preventing relapse. The discussion underscores the complexity of counseling conversations, which may last up to an hour per patient.

Biomarker selection remains an unmet need. While relative benefit may be demonstrated in trials, clinicians still lack robust tools to identify which patients truly require intensification. The panel highlights the importance of individualized risk assessment rather than uniform adoption of more aggressive adjuvant combinations.

Overall, this segment emphasizes that adjuvant therapy selection requires careful balancing of disease biology, patient goals, tolerability, and long term planning.